Calliditas Therapeutics Ab [CALT]

Source: 

Company Overview

We are a commercial-stage biopharmaceutical company with an FDA-approved product, Nefecon (marketed in the United States under the name TARPEYO), for patients with the autoimmune renal disease immunoglobulin A, or IgA, nephropathy, and a portfolio of innovative product candidates. The U.S. Food and Drug Administration, or FDA, granted accelerated approval to TARPEYO on December15, 2021 and we reported commercial availability in January2022.